Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells 12,500 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,500 shares of the business’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company’s stock, valued at approximately $20,665,399.68. This trade represents a 1.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Enliven Therapeutics Stock Up 0.8 %

Shares of NASDAQ ELVN traded up $0.16 on Friday, hitting $21.08. The company had a trading volume of 407,065 shares, compared to its average volume of 268,669. Enliven Therapeutics, Inc. has a 12-month low of $15.96 and a 12-month high of $30.03. The business has a 50 day moving average of $21.32 and a two-hundred day moving average of $23.76. The firm has a market capitalization of $1.03 billion, a P/E ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ELVN shares. HC Wainwright boosted their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research report on Friday. BTIG Research assumed coverage on Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Buy” and an average price target of $38.75.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company’s stock valued at $146,157,000 after buying an additional 199,692 shares in the last quarter. Polar Capital Holdings Plc raised its stake in Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after buying an additional 1,739,668 shares in the last quarter. Vanguard Group Inc. raised its stake in Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company’s stock valued at $44,452,000 after buying an additional 55,283 shares in the last quarter. Janus Henderson Group PLC raised its stake in Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock valued at $30,001,000 after buying an additional 290,153 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its stake in Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock valued at $21,877,000 after buying an additional 135,969 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.